MedPage Today on MSN
Dual targeting of GPRC5D and BCMA gets high response rate in extramedullary myeloma
O RLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination ...
The presentation and publication of the BRUIN CLL-314 trial followed the FDA’s December 3 decision to expand approval for ...
The addition of epcoritamab to standard therapy significantly improved PFS for patients with relapsed or refractory ...
The best CD yield from a national bank is Genisys Credit Union with a 4.40% APY on a 7-month CD with a $500 minimum to earn ...
Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...
Noncovalent Bruton tyrosine kinase inhibitors like pirtobrutinib may be a more effective first-line therapy for chronic ...
Commissioner Gary Bettman has called it "a ridiculous issue," but players overwhelmingly say it is a factor in where they ...
Mississippi faces a worsening obesity crisis, with projections showing 57% of adults could be classified as obese by 203 ...
Prime Minister Benjamin Netanyahu pressed Bank of Israel Governor Amir Yaron to lower interest rates during a meeting Thursday evening, according to the Kan public broadcaster.
Tai chi showed long-term benefits for long-term management of chronic insomnia that were on par with CBT, the first-line ...
Fairview Park Mayor Bill Schneider's comment during a council meeting about Gemini Center fee increases draws criticism from ...
In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results